Presentation to indicate how ERA™-treated T cells reveal improved cancer-killing capability and promise to cut back price of producing immune remedy medicines
MOUNTAIN VIEW, Calif., Feb. 28, 2023 /PRNewswire/ — Flip Biotechnologies, a cell rejuvenation firm creating novel mRNA medicines to treatment untreatable, age-related circumstances, at this time will current knowledge exhibiting that its ERA™ know-how can be utilized to dramatically enhance T cells’ capacity to battle most cancers.
Epigenetic Reprogramming of Getting old (ERA™) know-how along side the eTurna Supply Platform eradicated manufacturing-induced differentiation and accelerated exhaustion of CAR-T cell therapies, which guarantees to make CAR-T cell remedy extra accessible and less expensive.
The preclinical knowledge might be shared throughout a presentation by Mustafa Turkoz, PhD, Flip Bio Immunology, that may present ERA-treated T cells end in more practical, safer drug product, probably translating to superior affected person outcomes, lowered prices, and elevated affected person accessibility.
Presentation particulars are:
- Title: “Transient Epigenetic Reprogramming Enhances CAR-T-cell Proliferation and Tumor Killing”.
- Location: Room 29 CD, Higher Degree, within the San Diego Conference Heart in the course of the Subsequent Era CAR & T Cell Therapies Session.
- Date and Time: Tuesday, February 28, 2023, at 4:30 p.m. Pacific Time.
The Subsequent Era CAR & T Cell Therapies Convention is a part of BioProcess Worldwide US West, which is devoted to exploring the newest improvements in biopharmaceutical improvement and manufacturing.
ABOUT TURN BIOTECHNOLOGIES
Flip Bio is a pre-clinical-stage firm centered on repairing tissue on the mobile degree and creating transformative drug supply programs. The corporate’s proprietary mRNA platform know-how, ERA™ (Epigenetic Reprogramming of Getting old), restores optimum gene expression by combatting the consequences of ageing within the epigenome. This restores cells’ capacity to stop or deal with illness and heal or regenerate tissue. It’s going to assist to battle incurable persistent ailments. Its eTurna™ Supply Platform makes use of distinctive formulations to exactly ship cargo to particular organs, tissues, and cell varieties
The corporate is finishing pre-clinical analysis on tailor-made therapies focusing on indications in dermatology and immunology, and creating therapies for ophthalmology, osteo-arthritis, and the muscular system. For extra info, see www.flip.bio.
FOR MORE INFORMATION, CONTACT:
Jim Martinez, rightstorygroup
354585@email4pr.com or (312) 543-9026
View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/turn-biotechnologies-to-present-at-next-generation-car–t-cell-therapies-conference-on-february-28-301757908.html
SOURCE Flip Biotechnologies
